Helsinn Group and ESTEVE Renew Their Partnership Agreement
Helsinn Group and ESTEVE have recently finalized a renewal of their partnership in order to continue the commercialization of the drugs AKYNZEO and ALOXI in Germany. This renewed Distribution and License Agreement will help facilitate ongoing access to vital treatments for patients undergoing chemotherapy and dealing with its associated challenges.
Impact on Cancer Patient Care
The collaboration serves a significant purpose: ensuring that German patients have continuous access to two essential supportive care products in their battle against cancer. AKYNZEO combines netupitant and palonosetron, while ALOXI features palonosetron as its active ingredient. Both medications are used to mitigate chemotherapy-induced nausea and vomiting (CINV), a common and distressing side effect of cancer treatments.
Expert Insights on the Partnership
Klaus Schwarz, the Managing Director of ESTEVE Germany, expressed his enthusiasm for the agreement, stating how it reflects a shared commitment between the two companies. With this partnership, they aim to provide comprehensive support to patients navigating the complexities of their treatment journeys, reinforcing the importance of both AKYNZEO and ALOXI in enhancing patient care.
The Vision for Future Collaboration
The synergy between Helsinn and ESTEVE marks a commendable milestone in supportive cancer care. Dr. Melanie Rolli, CEO of Helsinn Group, emphasized the shared vision and dedication to improving the quality of life for patients. The aim is not only to manage symptoms effectively but also to explore innovative expansions in treatment options. This cooperative outlook is vital as the medical landscape continues to evolve.
Understanding AKYNZEO
AKYNZEO stands out as the first and only fixed combination of a 5-HT3 and NK1 receptor antagonist available for adults to help prevent both acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. Its ability to tackle these debilitating side effects makes it a crucial component of cancer treatment.
Exploring ALOXI's Role
ALOXI is specifically designed to prevent acute nausea and vomiting following highly emetogenic chemotherapy. Additionally, its application extends to pediatric patients aged one month and older. This diverse applicability underscores the importance of ALOXI in providing comprehensive care across different demographics facing similar challenges due to chemotherapy.
About ESTEVE
Founded in 1929, ESTEVE is a global pharmaceutical company based in Barcelona, Spain. With a mission to improve human lives through innovative therapies, the company has established a solid international presence, including pharmaceutical affiliates in various countries. Esteemed for their integrity and commitment, ESTEVE's focus remains on addressing significant unmet medical needs.
About Helsinn Group
Helsinn Group is dedicated to improving the quality of life for patients dealing with cancer and chronic diseases. Established in 1976 and headquartered in Lugano, Switzerland, Helsinn emphasizes supportive care, oncology, and dermato-oncology. The company operates globally with a commercial presence in over 90 countries.
Frequently Asked Questions
What is the significance of the Helsinn and ESTEVE partnership?
The partnership ensures continued access to AKYNZEO and ALOXI for patients in Germany, improving their treatment experience during chemotherapy.
What are AKYNZEO and ALOXI used for?
AKYNZEO is used for preventing nausea and vomiting caused by chemotherapy, while ALOXI targets acute nausea and vomiting in both adults and pediatric patients.
Where are HELSENN and ESTEVE headquartered?
Helsinn is based in Lugano, Switzerland, and ESTEVE operates from Barcelona, Spain.
When was the partnership between Helsinn and ESTEVE established?
The partnership has been in place for several years, and this renewal signifies their ongoing commitment to enhancing patient care.
How do AKYNZEO and ALOXI differ from each other?
AKYNZEO is a combination medication for broader chemotherapy-induced side effects, whereas ALOXI is specifically focused on preventing nausea and vomiting.
